Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,060
  • Shares Outstanding, K 52,743
  • Annual Sales, $ 0 K
  • Annual Income, $ -160,810 K
  • EBIT $ -160 M
  • EBITDA $ -165 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.71

Options Overview Details

View History
  • Implied Volatility 223.00% ( +29.26%)
  • Historical Volatility 123.87%
  • IV Percentile 84%
  • IV Rank 40.80%
  • IV High 528.24% on 08/26/24
  • IV Low 12.65% on 10/22/24
  • Put/Call Vol Ratio 12.50
  • Today's Volume 54
  • Volume Avg (30-Day) 153
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 5,174
  • Open Int (30-Day) 3,158

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.68
  • Number of Estimates 4
  • High Estimate -0.57
  • Low Estimate -0.81
  • Prior Year -0.93
  • Growth Rate Est. (year over year) +26.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2100 +33.88%
on 11/21/24
2.0500 -20.98%
on 12/18/24
+0.4100 (+33.88%)
since 11/20/24
3-Month
1.1900 +36.13%
on 11/19/24
2.0800 -22.12%
on 09/23/24
-0.4500 (-21.74%)
since 09/20/24
52-Week
1.1900 +36.13%
on 11/19/24
17.8250 -90.91%
on 05/07/24
-11.5400 (-87.69%)
since 12/20/23

Most Recent Stories

More News
ALX Oncology Announces Acceptance of Phase 2 ASPEN-06 Trial Results for Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology's clinical trial results for evorpacept will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.Quiver AI SummaryALX Oncology Holdings Inc. announced that the updated results...

ALXO : 1.6200 (+9.46%)
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – The American Cancer Society has unveiled its Advances in Oncology – 2024 Research Highlights report,...

ONCY : 0.8310 (-6.36%)
PSNL : 5.75 (+9.32%)
ALXO : 1.6200 (+9.46%)
ONC.TO : 1.19 (-9.16%)
NVCT : 4.52 (-3.62%)
TEM : 35.54 (+7.60%)
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALXO : 1.6200 (+9.46%)
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer

ALX Oncology will host a webcast on December 17 to discuss new clinical trial data for evorpacept in breast cancer.Quiver AI SummaryALX Oncology Holdings Inc. will host a virtual event on December 17,...

ALXO : 1.6200 (+9.46%)
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

ALXO : 1.6200 (+9.46%)
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

ALXO : 1.6200 (+9.46%)
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

ALXO : 1.6200 (+9.46%)
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALXO : 1.6200 (+9.46%)
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALXO : 1.6200 (+9.46%)
ALX Oncology Announces November Investor Conference Participation

ALXO : 1.6200 (+9.46%)

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 1.8500
2nd Resistance Point 1.7600
1st Resistance Point 1.6900
Last Price 1.6200
1st Support Level 1.5300
2nd Support Level 1.4400
3rd Support Level 1.3700

See More

52-Week High 17.8250
Fibonacci 61.8% 11.4704
Fibonacci 50% 9.5075
Fibonacci 38.2% 7.5446
Last Price 1.6200
52-Week Low 1.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar